Home » Blog » Company News

Company News

  • Asthma and Allergy Drug Development Is Failing Too Often--A Translational Reset Is Needed: HKEY-AIRx™1.0

    2026-02-03

    BOSTON and SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, today announced a translational preclinical strategy, HKEY-AIRxTM1.0 designed to address one of the most persistent problems facing biotech leadership: why Read More
  • HKeyBio Launches The HKEY-AIDMD 3.0--a Next-Generation Platform To Crack The Toughest Challenge in Autoimmune And Allergy Drug Development: Multi-target Combination Strategy Optimization

    2026-02-03

    The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platform for Read More
  • HKeyBio Lauched The Most Comprehesive Non-human Primate Autoimmune & Allergic Disease Model Matrix To Redefining Clinical Translation

    2026-02-03

    BOSTON and SUZHOU, China, Sept. 23, 2025 /PRNewswire/ -- HKeyBio, a CRO specializing in preclinical and translational autoimmune-drug development, today announced the launch of HKEY-NHP-MATRIX2.0, a next-generation platform designed to improve the reliability of translating novel autoimmune and alle Read More
  • CIA Model: The Key To Unveiling The Mechanisms of Multisystem Damage in Rheumatoid Arthritis

    2025-07-31

    CIA Model: The Key to Unveiling the Mechanisms of Multisystem Damage in Rheumatoid ArthritisRheumatoid arthritis (RA) is not merely a disorder confined to the joints; it is a complex, chronic inflammatory condition with far - reaching consequences. Read More
  • CIA Model: Innovative Applications of Collagen II Induced

    2025-07-24

    CIA Model: Innovative Applications of Collagen II InducedIn the dynamic field of life science research, the construction of disease models stands as a pivotal cornerstone. Read More
  • CIA Model: A Key Tool for Analyzing Autoimmune Response

    2025-07-17

    CIA Model: A Key Tool for Analyzing Autoimmune ResponseAutoimmune diseases, characterized by the immune system's abnormal attack on the body's own tissues, have become a global health challenge. Read More
  • CIA Model: The Core Tool for Gaining Insights into Synovial Inflammation

    2025-07-11

    CIA Model: The Core Tool for Gaining Insights into Synovial InflammationSynovial inflammation, a common pathological process in autoimmune arthritis and other joint - related diseases, poses a significant threat to human health. Read More
  • Deep Dive into The Association between CIA Model And Joint Destruction

    2025-07-07

    Deep Dive into the Association between CIA Model and Joint DestructionJoint destruction, a devastating consequence in autoimmune diseases such as rheumatoid arthritis, significantly impairs patients' mobility Read More
  • How the Pso Model Advances Psoriatic Arthritis Research

    2024-11-08

    IntroductionPsoriatic Arthritis (PsA) is an inflammatory arthritis associated with the skin condition Psoriasis. It can lead to joint damage and has a significant impact on patients’ quality of life. The complexity of PsA, with its multifaceted pathogenesis involving genetic, immunological, and envi Read More
  • Total 3 pages  Go to Page
  • Go
HKeybio is a Contract Research Organization (CRO) specializing in preclinical research within the field of autoimmune diseases.

Quick Links

Service Catagory

Contact Us

  Phone
Business Manager-Julie Lu:+86-18662276408
Business Inquiry-Will Yang:+86-17519413072
Technical Consultation-Evan Liu:+86-17826859169
us.bd@hkeybio.com; eu.bd@hkeybio.com; uk.bd@hkeybio.com.
  Add: Building B, No.388 Xingping Street, Ascendas iHub Suzhou Industrial Park, JIANGSU, CHINA
Leave a Message
CONTACT US
Sign up for our newsletter to receive the latest news.
​Copyright © 2024 HkeyBio. All rights reserved. | Sitemap | Privacy Policy